Dupilumab in Moderate-to-Severe Atopic Dermatitis: Pooled Efficacy Results from Two Identically Designed Randomized Phase 3 Trials (SOLO 1 & 2). J of Skin [Internet]. 2017 Oct. 27 [cited 2025 Apr. 19];1(3.1):s38. Available from: https://skin.dermsquared.com/skin/article/view/201